Krishna Malireddi, MD
Nephrology · Spokane, WANPI 1780778746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Akebia Therapeutics Inc at 24.6% of the total. Reporting peaked in 2023 at $759 and has fallen 52.5% since, to $360 in 2025.
Across 83 payments — averaging $38.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$778
- Travere Therapeutics, Inc.$390
- Amgen$305
- Otsuka America Pharmaceutical, Inc.$148
- AstraZeneca$143
- Vifor Pharma, Inc.$137
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,09198%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 6 | $778 |
| Travere Therapeutics, Inc. | 4 | $390 |
| Amgen(2 entities) | 10 | $305 |
| Otsuka America Pharmaceutical, Inc. | 2 | $148 |
| AstraZeneca(2 entities) | 5 | $143 |
| Vifor Pharma, Inc. | 3 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Aurinia Pharma U.S., Inc. | 1 | $114 |
| Corcept Therapeutics | 5 | $112 |
| GSK | 5 | $102 |
| Boehringer Ingelheim | 5 | $100 |
| Bayer | 5 | $83 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Novo Nordisk | 3 | $53 |
| Calliditas Therapeutics US Inc. | 2 | $49 |
| Johnson & Johnson | 2 | $48 |
| Insulet Corporation | 2 | $42 |
| Ardelyx, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 1 | $35 |
| Genentech USA, Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| UCB, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| EUSA Pharma (US) LLC | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AURYXIA$512
- LIVTENCITY$125
- LUPKYNIS$114
- Tavneos$101
- Veltassa$100
How this compares
$3,156 in reported general payments places this provider in the 85th percentile of 237 nephrology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 13 | $2,223 |
| Calcium Acetate | 19 | $1,168 |
| Calcitriol | 27 | $330 |
| Carvedilol | 49 | $328 |
| Amlodipine Besylate | 33 | $318 |
| Furosemide | 21 | $208 |
| Losartan Potassium | 18 | $154 |
| Hydralazine Hcl | 16 | $148 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Spokane
- Kathrine TuttleSpokane$421K
- Matthew RaySpokane$4K
- Saed NemrSpokane$4K
- Vijayakumar ReddySpokane$2K
- Nelson ChowSpokane$2K
- John MusaSpokane$1K
- Sean SanchezSpokane$1K
- Henry MrochSpokane$1K
- Nelio Guzman AguayoSpokane$1K
- Satinder SinghSpokane$942
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.